US › Healthcare

Editas Medicine Inc (EDIT)

US · Healthcare · Biotechnology

$2.35-3.69%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$11.9M

Revenue YoY

+232.3%

Net profit

$-18.2M

EPS

$-0.15

EPS estimate

$-0.30

Net margin

-153.3%

EPS came in at -0.15 against a street estimate of -0.30 — a beat of 50.0%.

Key statistics

Market cap

$375.5M

Forward P/E

0.0

P/B

3.89

Book value

$0.69

EPS (TTM)

$-0.68

52-week high

$4.33

52-week low

$1.66

50-day MA

$2.85

200-day MA

$2.65

Beta

2.00

Analyst view

Analysts rate Editas Medicine Inc a buy (8 buy, 3 hold, 2 sell out of 13) with an average price target of $6.10.

Shareholding

Insiders

0.18%

Institutions

79.37%

Largest institutional holders

Fund	Stake
TCG Crossover Management, LLC	7.23%
BlackRock Inc	6.90%
COMMODORE CAPITAL LP	5.79%
RA Capital Management, LLC	5.79%
ADAR1 Capital Management LLC	5.79%
Vanguard Capital Management, LLC	4.00%
Paradigm Biocapital Advisors LP	3.64%
Opaleye Management Inc	2.51%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Editas Medicine Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.